Form 4: Edwards Lifesciences Executive Larry L. Wood Reports Stock Transactions

Larry L. Wood, Global President of TAVR & Surg at Edwards Lifesciences, reports acquisition and disposal of common stock and derivative securities.

Summary

• On May 7, 2025, Larry L. Wood disposed of 819 shares of Edwards Lifesciences common stock at a price of $74.92.
• On May 8, 2025, Wood acquired 11,050 shares of common stock.
• Following these transactions, Wood directly owns 196,838.3913 shares and indirectly owns 148.1703 shares through a 401(k).
• Wood was also granted 62,000 employee stock options exercisable beginning June 8, 2025, and 11,050 performance rights scheduled to vest on May 8, 2028.
• The performance rights' vesting is contingent upon achieving certain performance goals over a three-year period, with the number of restricted stock units vesting ranging from 0% to 175% of the target awards.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of executive stock transactions. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency into the executive's holdings and recent activities.

Positives

• The granting of stock options and performance rights to a key executive like Larry L. Wood can be seen as a positive incentive for future performance.

Future Outlook

The vesting of restricted stock units and performance rights is contingent upon continued employment and the achievement of certain performance goals over a three-year period.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often used to align management's interests with those of shareholders. These transactions are closely watched by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option grants and performance-based equity awards are standard compensation practices among large-cap medical device companies such as Medtronic, Abbott, and Boston Scientific.
• The vesting schedules and performance metrics associated with these awards are typically designed to incentivize long-term value creation and retention of key talent.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in beneficial ownership of a key executive.
• The granting of stock options and performance rights could motivate the executive to improve company performance, benefiting shareholders and employees.

Key Dates

Keywords

Edwards Lifesciences, Larry L. Wood, Form 4, Stock Options, Performance Rights, Beneficial Ownership, TAVR, Stock Transactions